Vandetanib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 964 publications

From single to dual targeting: Recent advances in EGFR-based dual inhibitors for cancer therapy.

From single to dual targeting: Recent advances in EGFR-based dual inhibitors for cancer therapy.

Journal: European journal of medicinal chemistry

Published: August 03, 2026

Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review.

Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review.

Journal: Frontiers in endocrinology

Published: July 09, 2026

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

Journal: The Annals of pharmacotherapy

Published: June 30, 2026

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: June 24, 2026

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

Journal: JCO precision oncology

Published: June 08, 2026

Unravelling bioanalytical innovations, degradation processes, and impurity landscapes of VEGFR inhibitors.

Unravelling bioanalytical innovations, degradation processes, and impurity landscapes of VEGFR inhibitors.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: May 17, 2026

Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition.

Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition.

Journal: Frontiers in molecular biosciences

Published: May 07, 2026

Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.

Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.

Journal: International journal of molecular sciences

Published: May 07, 2026

Circulatory compromise as a potential mechanism of fatal hepatic failure during long-term selpercatinib therapy: pharmacokinetic and clinical insights.

Circulatory compromise as a potential mechanism of fatal hepatic failure during long-term selpercatinib therapy: pharmacokinetic and clinical insights.

Journal: Cancer chemotherapy and pharmacology

Published: May 06, 2026

Transcriptome profiling identifies RET activation as a therapeutic target in gastric-type endocervical adenocarcinoma.

Transcriptome profiling identifies RET activation as a therapeutic target in gastric-type endocervical adenocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 05, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research

Published: May 05, 2026

KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.

KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.

Journal: Oncology letters

Published: April 30, 2026

Showing 1-12 of 964

Last Updated: 11/08/2026